MX2020007671A - Terapia de combinacion para tratar o prevenir el cancer. - Google Patents

Terapia de combinacion para tratar o prevenir el cancer.

Info

Publication number
MX2020007671A
MX2020007671A MX2020007671A MX2020007671A MX2020007671A MX 2020007671 A MX2020007671 A MX 2020007671A MX 2020007671 A MX2020007671 A MX 2020007671A MX 2020007671 A MX2020007671 A MX 2020007671A MX 2020007671 A MX2020007671 A MX 2020007671A
Authority
MX
Mexico
Prior art keywords
treating
combination therapy
preventing cancer
cancer
preventing
Prior art date
Application number
MX2020007671A
Other languages
English (en)
Inventor
Alexander Stevenson
Original Assignee
4D Pharma Res Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1800927.4A external-priority patent/GB201800927D0/en
Priority claimed from GBGB1801502.4A external-priority patent/GB201801502D0/en
Priority claimed from GBGB1805941.0A external-priority patent/GB201805941D0/en
Priority claimed from GBGB1806572.2A external-priority patent/GB201806572D0/en
Priority claimed from GBGB1808628.0A external-priority patent/GB201808628D0/en
Application filed by 4D Pharma Res Limited filed Critical 4D Pharma Res Limited
Publication of MX2020007671A publication Critical patent/MX2020007671A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La invención provee una terapia de combinación que comprende una cepa bacteriana para el tratamiento y la prevención del cáncer.
MX2020007671A 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer. MX2020007671A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GBGB1800927.4A GB201800927D0 (en) 2018-01-19 2018-01-19 Combination therapy for treating or preventing cancer
GBGB1801502.4A GB201801502D0 (en) 2018-01-30 2018-01-30 Combination therapy for treating or preventing cancer
GBGB1805941.0A GB201805941D0 (en) 2018-04-10 2018-04-10 Combination therapy for treating or preventing cancer
GBGB1806572.2A GB201806572D0 (en) 2018-04-23 2018-04-23 Combination therapy for treating or preventing cancer
GBGB1808628.0A GB201808628D0 (en) 2018-05-25 2018-05-25 Combination therapy for treating or preventing cancer
PCT/GB2019/050141 WO2019141996A1 (en) 2018-01-19 2019-01-18 Combination therapy for treating or preventing cancer

Publications (1)

Publication Number Publication Date
MX2020007671A true MX2020007671A (es) 2020-09-14

Family

ID=65228590

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020007671A MX2020007671A (es) 2018-01-19 2019-01-18 Terapia de combinacion para tratar o prevenir el cancer.

Country Status (18)

Country Link
US (3) US20210060095A1 (es)
EP (1) EP3740218A1 (es)
JP (1) JP2021516216A (es)
KR (1) KR20200111183A (es)
CN (1) CN111629739A (es)
AU (1) AU2019210002A1 (es)
BR (1) BR112020014676A2 (es)
CA (1) CA3088413A1 (es)
CL (1) CL2020001888A1 (es)
CO (1) CO2020010013A2 (es)
IL (1) IL275949A (es)
MA (1) MA51613A (es)
MX (1) MX2020007671A (es)
NI (1) NI202000052A (es)
PH (1) PH12020551080A1 (es)
SG (1) SG11202006871YA (es)
TW (1) TW201938180A (es)
WO (1) WO2019141996A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202310861A (zh) * 2021-09-14 2023-03-16 英商4D製藥研究有限公司 包含細菌菌株之組合物
WO2023041574A1 (en) * 2021-09-14 2023-03-23 4D Pharma Research Limited Compositions comprising bacterial strains
CN113995835A (zh) * 2021-10-09 2022-02-01 山东新创生物科技有限公司 戈氏梭菌芽孢联合pd-1抗体的应用
WO2023072968A1 (en) * 2021-10-25 2023-05-04 4D Pharma Research Ltd Compositions comprising bacterial strains
KR102850602B1 (ko) * 2023-01-19 2025-08-26 재단법인 대구경북첨단의료산업진흥재단 골 질환 예방 또는 치료를 위한 신규 유산균 및 이의 배양액

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0127916D0 (en) 2001-11-21 2002-01-16 Rowett Res Inst Method
RU2420538C2 (ru) 2006-10-27 2011-06-10 Пфайзер Продактс Инк. Жесткие капсулы из гидроксипропилметилцеллюлозы и способ их получения
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
WO2016196605A1 (en) * 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
AU2016357554B2 (en) 2015-11-20 2019-04-04 Cj Bioscience, Inc. Compositions comprising bacterial strains
TW201907931A (zh) * 2017-05-24 2019-03-01 英商4D製藥研究有限公司 包含細菌菌株之組合物

Also Published As

Publication number Publication date
IL275949A (en) 2020-08-31
PH12020551080A1 (en) 2021-08-02
CN111629739A (zh) 2020-09-04
US20230048366A1 (en) 2023-02-16
US20210060095A1 (en) 2021-03-04
WO2019141996A1 (en) 2019-07-25
JP2021516216A (ja) 2021-07-01
EP3740218A1 (en) 2020-11-25
CA3088413A1 (en) 2019-07-25
CL2020001888A1 (es) 2020-12-18
AU2019210002A1 (en) 2020-08-13
BR112020014676A2 (pt) 2020-12-08
KR20200111183A (ko) 2020-09-28
TW201938180A (zh) 2019-10-01
MA51613A (fr) 2020-11-25
SG11202006871YA (en) 2020-08-28
US20240016861A1 (en) 2024-01-18
CO2020010013A2 (es) 2020-08-31
NI202000052A (es) 2021-01-20

Similar Documents

Publication Publication Date Title
MX2021000710A (es) Composiciones que comprenden cepas bacterianas.
PH12020551080A1 (en) Combination therapy for treating or preventing cancer
MX2020003770A (es) Terapias de combinacion para tratar cancer.
MX2021003903A (es) Terapia combinada para el melanoma.
EA201991818A1 (ru) Лечение рака
MX2022007955A (es) Regimenes de dosificacion de erdafitinib.
MX383066B (es) Composiciones que comprenden cepas bacterianas.
MX2020007664A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2017016114A (es) Metodos para tratar o prevenir una proteopatia.
MX2020008195A (es) Compuestos para el tratamiento del dolor.
PH12021551949A1 (en) Cancer treatment
MX2020007665A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2020007681A (es) Terapia de combinacion para tratar o prevenir el cancer.
MX2019009199A (es) Composiciones y métodos para modular ppp2r1a.
PH12022550610A1 (en) Antibiotic combination therapies
EA202091730A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091635A1 (ru) Комбинированная терапия для лечения или профилактики рака
EA202091636A1 (ru) Комбинированная терапия для лечения или профилактики рака
HK40039359A (en) Combination therapy for treating or preventing cancer
HK40039355A (en) Combination therapy for treating or preventing cancer
HK40039356A (en) Combination therapy for treating or preventing cancer
HK40039358A (en) Combination therapy for treating or preventing cancer
MX2021013776A (es) Composiciones que comprenden cepas bacterianas.
PH12021550101A1 (en) Cardio- and renosafe antidiabetic therapy
HK40080960A (en) Combination therapy for treating cancer